Douglas C Palmer

List of Publications by Year
in descending order

77 papers	15,087 citations	46918 47 h-index	98622 67 g-index
81 all docs	81 docs citations	81 times ranked	16410 citing authors

#	Article	IF	Citations
1	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. Journal of Experimental Medicine, 2005, 202, 907-912.	4.2	951
2	Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells. Journal of Experimental Medicine, 2003, 198, 569-580.	4.2	865
3	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine, 2009, 15, 808-813.	15.2	839
4	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation, 2005, 115, 1616-1626.	3.9	815
5	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9571-9576.	3.3	810
6	Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, 112, 362-373.	0.6	719
7	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. Journal of Clinical Investigation, 2013, 123, 4479-4488.	3.9	719
8	CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells. Journal of Immunology, 2005, 174, 2591-2601.	0.4	662
9	IL-15 enhances thein vivoantitumor activity of tumor-reactive CD8+T Cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1969-1974.	3.3	499
10	Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature, 2016, 537, 539-543.	13.7	479
11	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 2197-2204.	3.9	456
12	Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends in Immunology, 2005, 26, 111-117.	2.9	410
13	Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature. Immunity, 2011, 35, 972-985.	6.6	392
14	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood, 2008, 111, 5326-5333.	0.6	380
15	T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science, 2019, 363, .	6.0	355
16	Adoptively transferred effector cells derived from naÃ¯ve rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17469-17474.	3.3	348
17	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metabolism, 2016, 23, 63-76.	7.2	291
18	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. Cancer Research, 2015, 75, 296-305.	0.4	283

#	Article	IF	Citations
19	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. Immunity, 2013, 38, 742-753.	6.6	278
20	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 2011, 117, 808-814.	0.6	272
21	High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Molecular Therapy, 2006, 13, 151-159.	3.7	260
22	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research, 2011, 17, 5343-5352.	3.2	247
23	Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells. Journal of Immunotherapy, 2010, 33, 1-7.	1.2	236
24	Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends in Immunology, 2009, 30, 592-602.	2.9	229
25	Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts. Cancer Research, 2010, 70, 6725-6734.	0.4	227
26	BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers. Nature Immunology, 2016, 17, 851-860.	7.0	221
27	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. Cell, 2016, 166, 1117-1131.e14.	13.5	203
28	Memory T cellâ€"driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 2015, 126, 318-334.	3.9	193
29	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. Journal of Clinical Investigation, 2007, 117, 492-501.	3.9	181
30	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunology, 2011, 12, 1230-1237.	7.0	165
31	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. Journal of Experimental Medicine, 2015, 212, 2095-2113.	4.2	147
32	Retinoic acid controls the homeostasis of pre-cDCâ€"derived splenic and intestinal dendritic cells. Journal of Experimental Medicine, 2013, 210, 1961-1976.	4.2	120
33	Toll-like Receptors in Tumor Immunotherapy. Clinical Cancer Research, 2007, 13, 5280-5289.	3.2	114
34	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8061-8066.	3.3	114
35	Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction. Journal of Immunology, 2004, 173, 7209-7216.	0.4	110
36	Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. Journal of Immunology, 2006, 176, 5255-5266.	0.4	109

#	Article	IF	Citations
37	miR-155 augments CD8 ⁺ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic Î³ _c cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 476-481.	3.3	99
38	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular and Molecular Immunology, 2016, 13, 502-513.	4.8	99
39	Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell, 2020, 37, 818-833.e9.	7.7	96
40	Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma. Ophthalmology, 2009, 116, 981-989.e1.	2.5	88
41	Inhibition of TGF-Î² signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Therapy, 2013, 20, 575-580.	2.3	87
42	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Journal of Experimental Medicine, 2021, 218, .	4.2	84
43	T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. Journal of Immunotherapy, 2008, 31, 1-6.	1.2	63
44	Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas. Molecular Therapy, 2013, 21, 1369-1377.	3.7	62
45	CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood, 2006, 108, 3818-3823.	0.6	59
46	Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells. Journal of Immunotherapy, 2005, 28, 517-524.	1.2	57
47	Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Molecular Cancer Therapeutics, 2006, 5, 2592-2599.	1.9	49
48	The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor. Cancer Research, 2006, 66, 1132-1138.	0.4	49
49	The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 2016, 126, 599-604.	3.9	49
50	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology, 2004, 76, 333-337.	1.5	43
51	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood, 2008, 112, 4746-4754.	0.6	39
52	Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells. PLoS Pathogens, 2009, 5, e1000457.	2.1	35
53	Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Reports, 2018, 22, 3175-3190.	2.9	35
54	Inflammatory mediator production in swine following endotoxin challenge with or without co-administration of dexamethasone. International Immunopharmacology, 2003, 3, 571-579.	1.7	32

#	Article	IF	Citations
55	The Cish SH2 domain is essential for PLC-Î³1 regulation in TCR stimulated CD8+ T cells. Scientific Reports, 2018, 8, 5336.	1.6	32
56	Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology, 2006, 119, 63-73.	2.0	30
57	Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood, 2009, 114, 1776-1783.	0.6	26
58	Identification of the Genomic Insertion Site of Pmel-1 TCR Î± and Î² Transgenes by Next-Generation Sequencing. PLoS ONE, 2014, 9, e96650.	1.1	24
59	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	1.6	24
60	A T cell resilience model associated with response to immunotherapy in multiple tumor types. Nature Medicine, 2022, 28, 1421-1431.	15.2	23
61	Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. Journal of Clinical Investigation, 2010, 120, 4273-4288.	3.9	19
62	IFNâ€Î³â€receptor signaling ameliorates transplant vasculopathy through attenuation of CD8⁺ Tâ€cellâ€mediated injury of vascular endothelial cells. European Journal of Immunology, 2010, 40, 733-743.	1.6	18
63	TSCOT + Thymic Epithelial Cell-Mediated Sensitive CD4 Tolerance by Direct Presentation. PLoS Biology, 2008, 6, e191.	2.6	16
64	Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. Blood, 2008, 111, 4588-4595.	0.6	13
65	Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules. Gene Therapy, 2015, 22, 781-792.	2.3	7
66	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular and Molecular Immunology, 0, , .	4.8	7
67	Internal Checkpoint Regulates T Cell Neoantigen Reactivity and Susceptibility to PD1 Blockade. SSRN Electronic Journal, 0, , .	0.4	3
68	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 3140-3140.	3.9	2
69	Elevated potassium levels suppress T cell activation within tumors. , 2015, 3, .		2
70	333â€...Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program. , 2020, 8, A359-A359.		2
71	Cish attenuates proximal TCR-signaling and CD8+ T cell immunity. , 2014, 2, .		1
72	Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance. , 2015, 3, .		0

#	Article	IF	Citations
73	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. Blood, 2006, 108, 5210-5210.	0.6	0
74	IL-17A-Expressing CD4+ T Cells Must Acquire the Expression of T-Bet and IFN-Î³to Destroy Tumor Cells In Vivo.. Blood, 2009, 114, 468-468.	0.6	0
75	Abstract 1347: Genomic stress in antigen experienced T-lymphocytes. , 2015, , .		0
76	CD4+T Cells Are Programmed to Differentiate Before Entry into Division. , 2016, , .		0
77	Abstract 1463: Ionic immune suppression within the tumor microenvironment limits T cell effector function. , 2016, , .		0